These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33283981)

  • 1. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.
    Nangaku M; Kondo K; Takabe S; Ueta K; Kaneko G; Otsuka M; Kawaguchi Y; Komatsu Y
    Ther Apher Dial; 2021 Oct; 25(5):642-653. PubMed ID: 33283981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.
    Nangaku M; Kondo K; Takabe S; Ueta K; Tandai T; Kawaguchi Y; Komatsu Y
    Ther Apher Dial; 2022 Feb; 26(1):45-54. PubMed ID: 34115437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
    Eckardt KU; Agarwal R; Aswad A; Awad A; Block GA; Bacci MR; Farag YMK; Fishbane S; Hubert H; Jardine A; Khawaja Z; Koury MJ; Maroni BJ; Matsushita K; McCullough PA; Lewis EF; Luo W; Parfrey PS; Pergola P; Sarnak MJ; Spinowitz B; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Zwiech R; Chertow GM
    N Engl J Med; 2021 Apr; 384(17):1601-1612. PubMed ID: 33913638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
    Pergola PE; Spinowitz BS; Hartman CS; Maroni BJ; Haase VH
    Kidney Int; 2016 Nov; 90(5):1115-1122. PubMed ID: 27650732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies.
    Nangaku M; Ueta K; Nishimura K; Sasaki K; Hashimoto T
    Clin Exp Nephrol; 2024 May; 28(5):391-403. PubMed ID: 38530490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
    Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
    Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
    Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
    N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics.
    Chertow GM; Pergola PE; Agarwal R; Block GA; Farag YMK; Jardine AG; Koury MJ; Luo W; Khawaja Z; Lewis EF; Matsushita K; McCullough PA; Parfrey PS; Wittes J; Walters KA; Tseng C; Lin T; Sarnak MJ; Vargo DL; Winkelmayer WC; Eckardt KU
    Am Heart J; 2021 May; 235():1-11. PubMed ID: 33129989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis.
    Sarnak MJ; Agarwal R; Boudville N; Chowdhury PCP; Eckardt KU; Gonzalez CR; Kooienga LA; Koury MJ; Ntoso KA; Luo W; Parfrey PS; Vargo DL; Winkelmayer WC; Zhang Z; Chertow GM
    Nephrol Dial Transplant; 2023 Sep; 38(10):2358-2367. PubMed ID: 37096396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Comparison between Vadadustat and Daprodustat Regarding Dose, Cost, and Safety of Treatment for Renal Anemia in Non-dialysis Patients with Chronic Kidney Diseases.
    Imai E; Imai A
    Intern Med; 2024 Jul; 63(13):1855-1861. PubMed ID: 37926547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study.
    Nangaku M; Kondo K; Ueta K; Kokado Y; Kaneko G; Matsuda H; Kawaguchi Y; Komatsu Y
    Nephrol Dial Transplant; 2021 Aug; 36(9):1731-1741. PubMed ID: 33650630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials.
    Eckardt KU; Agarwal R; Farag YM; Jardine AG; Khawaja Z; Koury MJ; Luo W; Matsushita K; McCullough PA; Parfrey P; Ross G; Sarnak MJ; Vargo D; Winkelmayer WC; Chertow GM
    Nephrol Dial Transplant; 2021 Nov; 36(11):2039-2048. PubMed ID: 33188693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients.
    Kanai H; Nangaku M; Nagai R; Okuda N; Kurata K; Nagakubo T; Endo Y; Cobitz A
    Ther Apher Dial; 2021 Dec; 25(6):979-987. PubMed ID: 33964183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
    Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
    Akizawa T; Otsuka T; Reusch M; Ueno M
    Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.
    Haase VH; Chertow GM; Block GA; Pergola PE; deGoma EM; Khawaja Z; Sharma A; Maroni BJ; McCullough PA
    Nephrol Dial Transplant; 2019 Jan; 34(1):90-99. PubMed ID: 29672740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease.
    Mimura I; Tanaka T; Nangaku M
    Expert Opin Pharmacother; 2024 Jun; 25(9):1111-1120. PubMed ID: 38896547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vadadustat: First Approval.
    Markham A
    Drugs; 2020 Sep; 80(13):1365-1371. PubMed ID: 32852744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease.
    Navarro-Gonzales P; Ganz T; Pergola PE; Zuk A; Dykstra K
    Clin Pharmacol Ther; 2024 Oct; 116(4):1052-1061. PubMed ID: 38924087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease.
    Koury MJ; Agarwal R; Chertow GM; Eckardt KU; Fishbane S; Ganz T; Haase VH; Hanudel MR; Parfrey PS; Pergola PE; Roy-Chaudhury P; Tumlin JA; Anders R; Farag YMK; Luo W; Minga T; Solinsky C; Vargo DL; Winkelmayer WC
    Am J Hematol; 2022 Sep; 97(9):1178-1188. PubMed ID: 35751858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.